Home About History
History
2012 2014 2018 2019 2020 2021 2022 2023
2012
2012
Company name changed to CASI
2012
2014
EVOMELA® commercialization rights in China including, Hong Kong, Macau and Taiwan
2018
Launched R&D Production Site
EVOMELA® NMPA Approval
2019
CID-103 global intellectual property rights
CNCT-19 global co-commercialization rights
2019
2020
BI-1206 commercialization rights in China including, Hong Kong, Macau and Taiwan
Thiotepa commercialization rights in China
2021
CB-5339 global intellectual property rights
2022
Wuxi site obtained GSP distribution certificate
Over 10,000 patients treated with EVOMELA® in China
2022
2023
Folotyn® commercialization rights in mainland China
2023